https://www.selleckchem.com/pr....oducts/pilaralisib-x
findings may explain how PDE inhibitors can affect symptoms of the overactive bladder.Cancer cells have differential metabolic dependencies compared to their nonmalignant counterparts. However, few metabolism-targeting compounds have been successful in clinical trials. Here, we investigated the metabolic vulnerabilities of triple-negative breast cancer (TNBC), particularly those metabolic perturbations that increased mitochondrial apoptotic priming and sensitivity to BH3 mimetics (drugs that antagonize antiapoptotic proteins).
Like
Comment
Share
